

Siver Andreas Moestue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3324827/publications.pdf>

Version: 2024-02-01

60
papers

1,722
citations

236925

25
h-index

289244

40
g-index

63
all docs

63
docs citations

63
times ranked

3268
citing authors

#	ARTICLE	IF	CITATIONS
1	Phosphatase of regenerating liver β regulates cancer cell metabolism in multiple myeloma. <i>FASEB Journal</i> , 2021, 35, e21344.	0.5	19
2	Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft. <i>Nanomaterials</i> , 2021, 11, 1140.	4.1	7
3	Detection of phenotype β -specific therapeutic vulnerabilities in breast cells using a CRISPR loss β -function screen. <i>Molecular Oncology</i> , 2021, 15, 2026-2045.	4.6	3
4	EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition. <i>Molecular Cancer Research</i> , 2021, 19, 1546-1558.	3.4	6
5	Polymerization as a Strategy to Improve Small Organic Matrices for Low-Molecular-Weight Compound Analytics with MALDI MS and MALDI MS Imaging. <i>ACS Applied Polymer Materials</i> , 2021, 3, 4234-4244.	4.4	4
6	Reproducible Lipid Alterations in Patient-Derived Breast Cancer Xenograft FFPE Tissue Identified with MALDI MSI for Pre-Clinical and Clinical Application. <i>Metabolites</i> , 2021, 11, 577.	2.9	9
7	Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer. <i>Npj Systems Biology and Applications</i> , 2021, 7, 36.	3.0	3
8	Classification and biomarker identification of prostate tissue from TRAMP mice with hyperpolarized ^{13}C -SIRA. <i>Talanta</i> , 2021, 235, 122812.	5.5	11
9	Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 195-207.	7.3	31
10	Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. <i>Scientific Reports</i> , 2020, 10, 16992.	3.3	21
11	Detection of Recurrent Prostate Cancer With ^{18}F -Fluciclovine PET/MRI. <i>Frontiers in Oncology</i> , 2020, 10, 582092.	2.8	9
12	Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4800.	4.1	13
13	Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 61.	5.0	42
14	Detection and Differentiation of Breast Cancer Sub-Types using a cPLA2 β Activatable Fluorophore. <i>Scientific Reports</i> , 2019, 9, 6122.	3.3	15
15	O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes. <i>Scientific Reports</i> , 2019, 9, 5670.	3.3	23
16	NMR β -based metabolomics of biofluids in cancer. <i>NMR in Biomedicine</i> , 2019, 32, e3927.	2.8	29
17	R2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 T. <i>Tomography</i> , 2019, 5, 308-319.	1.8	4
18	Biomarker Discovery Using NMR-Based Metabolomics of Tissue. <i>Methods in Molecular Biology</i> , 2019, 2037, 243-262.	0.9	5

#	ARTICLE	IF	CITATIONS
19	18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. <i>European Radiology</i> , 2018, 28, 3151-3159.	4.5	59
20	Combined ¹⁸ F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 762-768.	5.0	27
21	Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1589-1600.	3.4	11
22	NMR-Based Prostate Cancer Metabolomics. <i>Methods in Molecular Biology</i> , 2018, 1786, 237-257.	0.9	9
23	APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. <i>Oncotarget</i> , 2018, 9, 11752-11766.	1.8	33
24	Investigation of Tumor Metabolism by High-resolution Magic-angle Spinning (HR-MAS) Magnetic Resonance Spectroscopy (MRS). <i>New Developments in NMR</i> , 2018, , 151-167.	0.1	0
25	Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. <i>Scientific Reports</i> , 2017, 7, 2046.	3.3	85
26	Pharmacokinetics of Perfluorobutane after Intra-Venous Bolus Injection of Sonazoid in Healthy Chinese Volunteers. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 1031-1039.	1.5	13
27	Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts. <i>Journal of Proteome Research</i> , 2017, 16, 1868-1879.	3.7	17
28	MR-Derived Biomarkers for Cancer Characterization. , 2017, , 409-431.		0
29	A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 695-703.	6.4	25
30	Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI. <i>Magnetic Resonance in Medicine</i> , 2017, 78, 1513-1522.	3.0	12
31	Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model. <i>Frontiers in Oncology</i> , 2017, 7, 290.	2.8	7
32	Abstract 1131: O-GlcNAc transferase inhibition in breast cancer cells. , 2017, , .		1
33	Abstract 4412: Metabolic reprogramming in EMT - targeting regulatory nodes in mesenchymal cells. , 2017, , .		0
34	Impact of Freezing Delay Time on Tissue Samples for Metabolomic Studies. <i>Frontiers in Oncology</i> , 2016, 6, 17.	2.8	40
35	Estrogen Receptor \pm Promotes Breast Cancer by Reprogramming Choline Metabolism. <i>Cancer Research</i> , 2016, 76, 5634-5646.	0.9	45
36	Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. <i>BMC Cancer</i> , 2016, 16, 191.	2.6	30

#	ARTICLE	IF	CITATIONS
37	Diffusion-weighted MRI for early detection and characterization of prostate cancer in the transgenic adenocarcinoma of the mouse prostate model. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 1207-1217.	3.4	15
38	Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. <i>Oncotarget</i> , 2016, 7, 12464-12476.	1.8	71
39	Abstract 3737: Inhibition of O-GlcNAc transferase in tamoxifen resistant breast cancer cells. , 2016, , .		0
40	Identification of Metastasis-Associated Metabolic Profiles of Tumors by 1H-HR-MAS-MRS. <i>Neoplasia</i> , 2015, 17, 767-775.	5.3	6
41	Metabolic reprogramming supports the invasive phenotype in malignant melanoma. <i>Cancer Letters</i> , 2015, 366, 71-83.	7.2	70
42	Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. <i>Nature Medicine</i> , 2015, 21, 955-961.	30.7	231
43	MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. <i>British Journal of Cancer</i> , 2015, 112, 504-513.	6.4	25
44	In Vivo ³¹ P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 601-609.	3.4	10
45	Quantitative ³¹ P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 1973-1981.	3.0	18
46	Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. <i>Breast Cancer Research</i> , 2014, 16, R5.	5.0	45
47	Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R16.	5.0	42
48	Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. <i>Molecular Oncology</i> , 2013, 7, 130-142.	4.6	26
49	Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1043-1053.	3.4	34
50	Intravascular Targets for Molecular Contrast-Enhanced Ultrasound Imaging. <i>International Journal of Molecular Sciences</i> , 2012, 13, 6679-6697.	4.1	29
51	Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2506; author reply E2507.	7.1	26
52	In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 1098-1107.	3.4	27
53	Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy. <i>Molecular Oncology</i> , 2011, 5, 224-241.	4.6	10
54	HR MAS MR Spectroscopy in Metabolic Characterization of Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2-26.	2.1	86

#	ARTICLE	IF	CITATIONS
55	¹³ C High-resolution magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns. NMR in Biomedicine, 2011, 24, 1243-1252.	2.8	18
56	MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR in Biomedicine, 2011, 24, 673-690.	2.8	81
57	Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer, 2010, 10, 433.	2.6	93
58	Whole-body section fluorescence imaging – a novel method for tissue distribution studies of fluorescent substances. Contrast Media and Molecular Imaging, 2009, 4, 73-80.	0.8	6
59	A targeted molecular probe for colorectal cancer imaging. , 2008, , .		2
60	Microemulsion electrokinetic chromatography in suppressed electroosmotic flow environment. Journal of Chromatography A, 2000, 876, 201-211.	3.7	81